HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs. PMID: 35563157
Molecular epidemiology of HIV. PMID: 15817947
Determinants in HIV-2 Env and tetherin required for functional interaction. PMID: 26248668
Intra-Patient Evolution of HIV-2 Molecular Properties. PMID: 36366545
HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. PMID: 20529266
Study of the HIV-2 Env cytoplasmic tail variability and its impact on Tat, Rev and Nef. PMID: 24223892
Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates. PMID: 27681141
Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism. PMID: 27754450
Bacterially produced HIV-2 env polypeptides specific for distinguishing HIV-2 from HIV-1 infections. PMID: 2187502
Cost-effective diagnosis of HIV-1 and HIV-2 by recombinant-expressed env peptide (566/996) dot-blot analysis. PMID: 8507413
Intrahost evolution of the HIV-2 capsid correlates with progression to AIDS. PMID: 36533148
The env protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation. PMID: 2364016
How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses? PMID: 25445493
Multispot HIV-1/HIV-2 Rapid Test: advantages over other rapid HIV tests. PMID: 17892358
HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution. PMID: 34422316
Recombinant peptides derived from the env-gene of HIV-2 in the serodiagnosis of HIV-2 infections. PMID: 2496732
HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. PMID: 7910884
Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon. PMID: 9866744
HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts. PMID: 9468361
Human immunodeficiency virus type 2 (HIV-2) env gene analysis: prediction of glycoprotein epitopes important for heterotypic neutralization and evidence for three genotype clusters within the HIV-2a subtype. PMID: 7531216
Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism. PMID: 29028477
Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa. PMID: 12908935
Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1 and ongoing transmission at the heart of the epidemic. PMID: 23032414
Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. PMID: 22933274
HIV-2 CRF01_AB: first circulating recombinant form of HIV-2. PMID: 20502347
Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity. PMID: 32521274
Antigenic and immunogenic sites of HIV-2 glycoproteins. PMID: 8452654
HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage. PMID: 25421818
Molecular analyses of HIV-1 group O and HIV-2 variants from Africa. PMID: 9209322
An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. PMID: 23324659
Cross-reactivity on western blots in HIV-1 and HIV-2 infections. PMID: 1892591
An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV. PMID: 9430248
Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein-Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2-Infected Individuals. PMID: 30715363
HIV-2 amino acid substitutions in Gag and Env proteins occurring simultaneously with viral load upsurge in a drug-naïve patient. PMID: 18622680
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. PMID: 19019969
Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 Rapid Test for classifying HIV-1 and HIV-2 infections. PMID: 21993309
HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. PMID: 20463072
Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. PMID: 20594957
Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. PMID: 7492438
Genomic divergence of HIV-2 from Ghana. PMID: 2611042
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. PMID: 17144914
Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. PMID: 17582003
A microELISA system for the detection of both anti-HIV-1 and anti-HIV-2 antibodies. PMID: 2040818
Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy., PMID:39586543
Epidemic characteristics of local HIV-2 transmission across Hunan province, China., PMID:38723949
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates., PMID:37240423
Cryo-EM structures of prefusion SIV envelope trimer., PMID:36344847
HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs., PMID:35563157
Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy., PMID:34821542
HIV envelope tail truncation confers resistance to SERINC5 restriction., PMID:34001619
Computational Modulation of the V3 Region of Glycoprotein gp125 of HIV-2., PMID:33669351
Selection and immune recognition of HIV-1 MPER mimotopes., PMID:32980676
Synthesis, Molecular Docking and Molecular Dynamics Simulation of 2- Thioxothiazolidin-4-One Derivatives against Gp41., PMID:32885756
CpG Frequency in the 5' Third of the env Gene Determines Sensitivity of Primary HIV-1 Strains to the Zinc-Finger Antiviral Protein., PMID:31937644
The involvement of the substance P/neurokinin 1 receptor system in viral infection: focus on the gp120 fusion protein and homologous dipeptide domains., PMID:31507190
Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope., PMID:31471224
Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors., PMID:31277353
The autophagy protein ATG9A promotes HIV-1 infectivity., PMID:31269971
eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody., PMID:31068428
Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity., PMID:30867304
Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein-Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2-Infected Individuals., PMID:30715363
The N-Terminus of the HIV-1 p6 Gag Protein Regulates Susceptibility to Degradation by IDE., PMID:30545091
Apolipoprotein E is an HIV-1-inducible inhibitor of viral production and infectivity in macrophages., PMID:30496280
Potent suppression of HIV-1 cell attachment by Kudzu root extract., PMID:30236131
Short Communication: An Insertion of Seven Amino Acids in the Envelope Cytoplasmic Tail of HIV-2 Selected During Disease Progression Enhances Viral Replication., PMID:30229676
Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2., PMID:29976668
Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses., PMID:29936340
Characterization of twin-cysteine motif in the V2-loop region of gp120 in primate lentiviruses., PMID:29729526
Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11., PMID:29618644
eCD4-Ig Variants That More Potently Neutralize HIV-1., PMID:29593050
Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus., PMID:29425101
Characterization of Envelope Surface Glycoprotein from HIV-2 Primary Isolates with Different Coreceptor Usage Profile., PMID:29258330
Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism., PMID:29028477
Proteolysis of mature HIV-1 p6 Gag protein by the insulin-degrading enzyme (IDE) regulates virus replication in an Env-dependent manner., PMID:28388673
A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity., PMID:28356533
RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction., PMID:28275184
A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support., PMID:27998283
A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus., PMID:27795437
Lineage-Specific Differences between the gp120 Inner Domain Layer 3 of Human Immunodeficiency Virus and That of Simian Immunodeficiency Virus., PMID:27535053
Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism., PMID:27754450
Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates., PMID:27681141
The V1 region of gp120 is preferentially selected during SIV/HIV transmission and is indispensable for envelope function and virus infection., PMID:27117672
Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability., PMID:27064278
Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors., PMID:27058352
The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition., PMID:26816344
Structure of an HIV-2 gp120 in Complex with CD4., PMID:26608312
Tropism distribution among antiretroviral-naive HIV-2-infected patients., PMID:26544584
IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein., PMID:26387945
Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its ability to detect HIV gp41 IgM antibodies., PMID:26311612
Determinants in HIV-2 Env and tetherin required for functional interaction., PMID:26248668
NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles., PMID:25700718
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency., PMID:25673728
[Use of a synthetic peptide of HIV-2 glycoprotein 36 in antigen mixtures for the immunodiagnosis of HIV types 1 and 2]., PMID:25639906
For research use only. Not for human or drug use.
